Cocce Valentina, Balducci Luigi, Falchetti Maria L, Pascucci Luisa, Ciusani Emilio, Brini Anna T, Sisto Francesca, Piovani Giovanna, Alessandri Giulio, Parati Eugenio, Cabeza Laura, Pessina Augusto
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133 Milan, Italy.
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Maxillofacial and Dental Unit. Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Commenda 10, 20122, Milan, Italy.
Anticancer Agents Med Chem. 2017 Nov 24;17(11):1578-1585. doi: 10.2174/1871520617666170327113932.
A new tool for the drug delivery is based on the use of Mesenchymal Stromal Cells (MSCs) loaded in vitro with anti-cancer drugs. Unfortunately, the restricted lifespan of MSCs represents a significant limitation to produce them in high amounts and for long time studies. Immortalized MSCs from adipose tissue (hASCs) have been generated as good source of cells with stable features. These cells could improve the development of standardized procedures for both in vitro and preclinical studies. Furthermore they facilitate procedures for preparing large amounts of secretome containing microvesicles (MVs).
We used human adipose tissue derived MSCs immortalized with hTERT+SV40 (TS) genes and transfected with GFP (hASCs-TS/GFP+). This line was investigated for its ability to uptake and release anticancer drugs. Microvesicles associated to paclitaxel (MVs/PTX) were isolated, quantified, and tested on pancreatic cancer cells.
The line hASCs-TS/GFP+ maintained the main mesenchymal characters and was able to uptake and release, in active form, both paclitaxel and gemcitabine. From paclitaxel loaded hASCs-TS/GFP+ cells were isolated microvesicles in sufficient amount to inhibit "in vitro" the proliferation of pancreatic tumor cells.
Our study suggests that human immortalized MSCs could be used for a large scale production of cells for mediated drug delivery. Moreover, the secretion of drug-associated MVs could represent a new way for producing new drug formulation by "biogenesis". In the context of the "advanced cell therapy procedure", the MVs/PTX production would use less resource and time and it could possibly contribute to simplification of GMP procedures.
一种新的药物递送工具基于体外加载抗癌药物的间充质基质细胞(MSC)的使用。不幸的是,MSC有限的寿命对大量生产它们以及进行长期研究构成了重大限制。来自脂肪组织的永生化MSC(hASC)已被培育出来,作为具有稳定特性的良好细胞来源。这些细胞可以改善体外和临床前研究标准化程序的发展。此外,它们便于制备含有微泡(MV)的大量分泌组的程序。
我们使用用hTERT + SV40(TS)基因永生化并转染GFP的人脂肪组织来源的MSC(hASC-TS/GFP+)。研究了该细胞系摄取和释放抗癌药物的能力。分离、定量与紫杉醇相关的微泡(MVs/PTX),并在胰腺癌细胞上进行测试。
hASC-TS/GFP+细胞系保持了主要的间充质特征,能够以活性形式摄取和释放紫杉醇和吉西他滨。从加载紫杉醇的hASC-TS/GFP+细胞中分离出足够量的微泡,以“体外”抑制胰腺肿瘤细胞的增殖。
我们的研究表明,人永生化MSC可用于大规模生产介导药物递送的细胞。此外,药物相关MV的分泌可能代表通过“生物发生”生产新药物制剂的新方法。在“先进细胞治疗程序”的背景下,MVs/PTX的生产将使用更少的资源和时间,并且可能有助于简化GMP程序。